K Fagan 9/23/25 K Fagan 9/23/25

Tylenol, Then and Now: Crisis Under New Ownership

September 23, 2025
Tylenol 1982 was J&J’s gold standard in crisis management. Tylenol 2025 will show whether Kenvue can live up to that legacy.

K Fagan 9/16/25 K Fagan 9/16/25

GLP-1 War of the Words Part II: The Contenders

September 16, 2025
Amgen and Viking aren’t just joining the GLP-1 race; they’re trying to tell a new story.

K Fagan 9/2/25 K Fagan 9/2/25

August 31, 2025
Drug development is hard.
Narrative resilience helps weather the storms.

K Fagan 8/20/25 K Fagan 8/20/25

August 20, 2025
Who’s telling the bolder, more credible story in this $63 billion market?

K Fagan 7/29/25 K Fagan 7/29/25

July 29, 2025
In its latest acquisition, Sanofi gives us subtle (and not-so-subtle) clues about how it’s rewriting its story.

K Fagan 7/1/25 K Fagan 7/1/25

July 1, 2025
Great science, plus a narrative that knew
what it was doing

K Fagan 6/15/25 K Fagan 6/15/25

June 15, 2025
Building your narrative is all about creating a shared understanding of your story.

K Fagan 6/12/25 K Fagan 6/12/25

June 12, 2025
Same company, different stories. No one’s wrong, but you’re sending mixed messages.

K Fagan 6/8/25 K Fagan 6/8/25

June 8, 2025
Are you expecting your audience to solve the puzzle of your story?

K Fagan 6/1/25 K Fagan 6/1/25

June 1, 2025
Why brilliant healthcare companies struggle to tell their story